Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00003854
Registration number
NCT00003854
Ethics application status
Date submitted
1/11/1999
Date registered
27/01/2003
Date last updated
13/07/2016
Titles & IDs
Public title
Prognostic Study of Sentinel Lymph Node and Bone Marrow Metastases in Women With Stage I or Stage IIA Breast Cancer
Query!
Scientific title
A Prognostic Study of Sentinel Node and Bone Marrow Micrometastases in Women With Clinical T1-2 N0 Breast Cancer
Query!
Secondary ID [1]
0
0
GUMC-00152
Query!
Secondary ID [2]
0
0
ACOSOG-Z0010
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - immunohistochemistry staining method
Treatment: Surgery - lymphangiography
Treatment: Surgery - sentinel lymph node biopsy
Treatment: Surgery - therapeutic conventional surgery
Treatment: Other - whole breast irradiation
Experimental: Surgery + radiotherapy + adjuvant therapy - Patients undergo bilateral anterior iliac crest bone marrow aspiration to test for presence of micrometastases. Patients then undergo breast-conserving therapy comprising segmental mastectomy and sentinel lymph node dissection (SLND) with planned postoperative whole-breast radiotherapy and systemic adjuvant therapy. The SLND comprises ipsilateral axillary sentinel node identification and histopathology.
Patients with no sentinel node identified intraoperatively and patients with sentinel node metastasis identified by hematoxylin and eosin (H&E) who choose not to be registered to ACOSOG-Z0011 undergo axillary lymph node dissection involving removal of at least level I and II nodes.
All patients undergo whole-breast radiotherapy (excluding a supraclavicular field) 5 days a week for a maximum of 8 weeks.
Patients are followed at 30 days; at 6, 12, 18, 24, 30, and 36 months; and then annually until 10 years after surgery.
Other interventions: immunohistochemistry staining method
Treatment: Surgery: lymphangiography
Treatment: Surgery: sentinel lymph node biopsy
Treatment: Surgery: therapeutic conventional surgery
Treatment: Other: whole breast irradiation
Query!
Intervention code [1]
0
0
Other interventions
Query!
Intervention code [2]
0
0
Treatment: Surgery
Query!
Intervention code [3]
0
0
Treatment: Other
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall survival
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Up to 10 years
Query!
Secondary outcome [1]
0
0
Disease-free survival
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Up to 10 years
Query!
Secondary outcome [2]
0
0
Axillary recurrence following detection of negative SN with H&E staining in women who did not have an ALND
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Up to 10 years
Query!
Eligibility
Key inclusion criteria
1. Patient must be female.
2. Patient's clinical stage must be I or II (T1 or T2 N0 M0) and the tumor must be
amenable to segmental mastectomy (lumpectomy).
3. Patient must have a tissue diagnosis of invasive breast carcinoma. Note: A patient can
be registered to this study if they have a cytologic diagnosis suggestive of carcinoma
from a fine needle aspiration (FNA) of a palpable or non-palpable breast lesion and
the investigator believes the breast lesion is clinically suspicious for invasive
breast carcinoma.
4. The date of the patient's first tissue diagnosis of invasive breast carcinoma or
cytologic diagnosis of breast carcinoma must be no more than 60 days prior to SLND.
5. The patient who had segmental mastectomy (lumpectomy) performed previously, and is now
referred to the local investigator for SLND, is eligible if the lumpectomy was less
than or equal to 60 days prior to the SLND. Copies of the operative and pathology
reports must be submitted as a part of the registration process.
6. Patient must have ECOG/Zubrod status of =2, as documented in patient's medical record.
7. Patient must be available for follow-up.
8. The patient with a history of a previous malignancy is eligible for this study as long
as the patient meets the following criteria for a cancer survivor. A cancer survivor
is eligible provided that the following criteria are met:
1. The patient has undergone potentially curative therapy for all prior
malignancies.
2. There has been no evidence of any prior malignancies for at least five years with
no evidence of recurrence (except for effectively treated basal cell or squamous
carcinoma of the skin, carcinoma in-situ of the cervix that has been effectively
treated by surgery alone, or lobular carcinoma in-situ of the ipsilateral or
contralateral breast treated by surgery alone), and
3. The patient is deemed by their treating physician to be at low risk for
recurrence from prior malignancies.
9. Signed and dated informed consent is obtained prior to patient registration.
10. Patients of childbearing potential must have a negative serum or urine pregnancy test
within 14 days of beginning study interventions.
11. Patient must be able to physically undergo bilateral anterior iliac crest bone marrow
aspiration.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Patient is lactating (breastfeeding).
2. Patient has been previously treated with chemotherapy, estrogen receptor antagonists
(i.e. Tamoxifen) or selective estrogen receptor modulators (SERMs, i.e. Raloxifene)
for this invasive breast cancer.
3. Patient has a previously placed pre-pectoral breast implant. NOTE: A subpectoral
implant is allowed.
4. Patient is considered a poor surgical risk due to a non-malignant systemic disease
(cardiovascular, renal, etc.), which would preclude the treatment options.
5. Patient has concurrent bilateral invasive breast malignancies.
6. Patient is not able to undergo and does not have access to radiation therapy as
describedin Adjuvant Radiation Therapy in the Interventions section of the protocol.
Patients with active connective tissue disorders and those that live too far from a
radiation treatment center, for example, would not be eligible.
7. Patient has clinically and radiologically identified multi-centric disease that is not
amenable to a single lumpectomy.
8. Patient has had previous ipsilateral axillary surgery such as excisional biopsy of
lymph node(s), treatment of hidradenitis.
Query!
Study design
Purpose of the study
Diagnosis
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/04/1999
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/07/2011
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
4590
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Peter MacCallum Cancer Institute - East Melbourne
Query!
Recruitment postcode(s) [1]
0
0
8006 - East Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Connecticut
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Delaware
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
District of Columbia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Florida
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Georgia
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Hawaii
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Idaho
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Illinois
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Indiana
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Kansas
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Kentucky
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Louisiana
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Maryland
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Massachusetts
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Michigan
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Minnesota
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Mississippi
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Missouri
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
New Hampshire
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
New Jersey
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
New York
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
North Carolina
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Ohio
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Pennsylvania
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Rhode Island
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Tennessee
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Texas
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Utah
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
Virginia
Query!
Country [35]
0
0
United States of America
Query!
State/province [35]
0
0
Washington
Query!
Country [36]
0
0
United States of America
Query!
State/province [36]
0
0
Wisconsin
Query!
Country [37]
0
0
Ireland
Query!
State/province [37]
0
0
Cork
Query!
Country [38]
0
0
Ireland
Query!
State/province [38]
0
0
Dublin
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Alliance for Clinical Trials in Oncology
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Government body
Query!
Name [1]
0
0
National Cancer Institute (NCI)
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
RATIONALE: Biopsy of sentinel lymph nodes and bone marrow may improve the ability to detect
and determine the extent of cancer.
PURPOSE: Phase III prognostic study of sentinel lymph node metastases and bone marrow
metastases in women who have stage I or stage IIA breast cancer.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00003854
Query!
Trial related presentations / publications
Olson JA Jr, McCall LM, Beitsch P, Whitworth PW, Reintgen DS, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Giuliano AE; American College of Surgeons Oncology Group Trials Z0010 and Z0011. Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011. J Clin Oncol. 2008 Jul 20;26(21):3530-5. doi: 10.1200/JCO.2007.15.5630.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Armando E. Giuliano, MD
Query!
Address
0
0
Saint John's Cancer Institute
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00003854
Download to PDF